Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation
- 28 December 2012
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 344 (3), 665-672
- https://doi.org/10.1124/jpet.112.201640
Abstract
Clopidogrel pharmacotherapy is associated with substantial interindividual variability in clinical response, which can translate into an increased risk of adverse outcomes. Clopidogrel, a recognized substrate of hepatic carboxylesterase 1 (CES1), undergoes extensive hydrolytic metabolism in the liver. Significant interindividual variability in the expression and activity of CES1 exists, which is attributed to both genetic and environmental factors. We determined whether CES1 inhibition and CES1 genetic polymorphisms would significantly influence the biotransformation of clopidogrel and alter the formation of the active metabolite. Coincubation of clopidogrel with the CES1 inhibitor bis(4-nitrophenyl) phosphate in human liver s9 fractions significantly increased the concentrations of clopidogrel, 2-oxo-clopidogrel, and clopidogrel active metabolite, while the concentrations of all formed carboxylate metabolites were significantly decreased. As anticipated, clopidogrel and 2-oxo-clopidogrel were efficiently hydrolyzed by the cell s9 fractions prepared from wild-type CES1 transfected cells. The enzymatic activity of the CES1 variants G143E and D260fs were completely impaired in terms of catalyzing the hydrolysis of clopidogrel and 2-oxo-clopidogrel. However, the natural variants G18V, S82L, and A269S failed to produce any significant effect on CES1-mediated hydrolysis of clopidogrel or 2-oxo-clopidogrel. In summary, deficient CES1 catalytic activity resulting from CES1 inhibition or CES1 genetic variation may be associated with higher plasma concentrations of clopidogrel-active metabolite, and hence may enhance antiplatelet activity. Additionally, CES1 genetic variants have the potential to serve as a biomarker to predict clopidogrel response and individualize clopidogrel dosing regimens in clinical practice.Keywords
This publication has 41 references indexed in Scilit:
- Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidateThe Pharmacogenomics Journal, 2012
- Carboxylesterase inhibitorsExpert Opinion on Therapeutic Patents, 2011
- Paraoxonase-1 is a major determinant of clopidogrel efficacyNature Medicine, 2010
- In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase ActivitiesDrug Metabolism and Disposition, 2010
- Platelet function testing and risk of bleeding complicationsThrombosis and Haemostasis, 2010
- A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and ClopidogrelPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2009
- Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genesPharmacogenetics and Genomics, 2008
- Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery DiseaseJournal of the American College of Cardiology, 2007
- Genomic Structure and Transcriptional Regulation of the Rat, Mouse, and Human Carboxylesterase GenesDrug Metabolism Reviews, 2007
- A Single Nucleotide Polymorphism in the Carboxylesterase Gene Is Associated with the Responsiveness to Imidapril Medication and the Promoter ActivityHypertension Research, 2005